- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01845649
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
11 april 2022 bijgewerkt door: Warner Chilcott
A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women With Dyspareunia
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
550
Fase
- Fase 3
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35211
- Warner Chilcott Investigational Study Site
-
Mobile, Alabama, Verenigde Staten, 36608
- Warner Chilcott Investigational Study Site
-
-
Arizona
-
Chandler, Arizona, Verenigde Staten, 85224
- Warner Chilcott Investigational Study Site
-
Phoenix, Arizona, Verenigde Staten, 85032
- Warner Chilcott Investigational Study Site
-
Scottsdale, Arizona, Verenigde Staten, 85251
- Warner Chilcott Investigational Study Site
-
Tucson, Arizona, Verenigde Staten, 85712
- Warner Chilcott Investigational Study Site
-
Tucson, Arizona, Verenigde Staten, 85710
- Warner Chilcott Investigational Study Site
-
-
California
-
Sacramento, California, Verenigde Staten, 95821
- Warner Chilcott Investigational Study Site
-
San Diego, California, Verenigde Staten, 92103
- Warner Chilcott Investigational Study Site
-
San Diego, California, Verenigde Staten, 92108
- Warner Chilcott Investigational Study Site
-
San Diego, California, Verenigde Staten, 92123
- Warner Chilcott Investigational Study Site
-
-
Connecticut
-
New London, Connecticut, Verenigde Staten, 06320
- Warner Chilcott Investigational Study Site
-
-
District of Columbia
-
Washington, District of Columbia, Verenigde Staten, 20036
- Warner Chilcott Investigational Study Site
-
-
Florida
-
Boynton Beach, Florida, Verenigde Staten, 33472
- Warner Chilcott Investigational Study Site
-
Clearwater, Florida, Verenigde Staten, 33759
- Warner Chilcott Investigational Study Site
-
Jacksonville, Florida, Verenigde Staten, 32216
- Warner Chilcott Investigational Study Site
-
Miami, Florida, Verenigde Staten, 33186
- Warner Chilcott Investigational Study Site
-
Ormond Beach, Florida, Verenigde Staten, 32174
- Warner Chilcott Investigational Study Site
-
Palm Beach Gardens, Florida, Verenigde Staten, 33410
- Warner Chilcott Investigational Study Site
-
Pinellas Park, Florida, Verenigde Staten, 33781
- Warner Chilcott Investigational Study Site
-
West Palm Beach, Florida, Verenigde Staten, 33409
- Warner Chilcott Investigational Study Site
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30342
- Warner Chilcott Investigational Study Site
-
Roswell, Georgia, Verenigde Staten, 30075
- Warner Chilcott Investigational Study Site
-
Savannah, Georgia, Verenigde Staten, 31406
- Warner Chilcott Investigational Study Site
-
-
Indiana
-
Granger, Indiana, Verenigde Staten, 46530
- Warner Chilcott Investigational Study Site
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40509
- Warner Chilcott Investigational Study Site
-
-
Louisiana
-
Marrero, Louisiana, Verenigde Staten, 70072
- Warner Chilcott Investigational Study Site
-
New Orleans, Louisiana, Verenigde Staten, 70115
- Warner Chilcott Investigational Study Site
-
-
Michigan
-
Kalamazoo, Michigan, Verenigde Staten, 49009
- Warner Chilcott Investigational Study Site
-
-
Minnesota
-
Chaska, Minnesota, Verenigde Staten, 55318
- Warner Chilcott Investigational Study Site
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89113
- Warner Chilcott Investigational Study Site
-
Las Vegas, Nevada, Verenigde Staten, 89128
- Warner Chilcott Investigational Study Site
-
-
New Jersey
-
Moorestown, New Jersey, Verenigde Staten, 08057
- Warner Chilcott Investigational Study Site
-
-
North Carolina
-
Greensboro, North Carolina, Verenigde Staten, 27408
- Warner Chilcott Investigational Study Site
-
New Bern, North Carolina, Verenigde Staten, 28562
- Warner Chilcott Investigational Study Site
-
Raleigh, North Carolina, Verenigde Staten, 27607
- Warner Chilcott Investigational Study Site
-
Winston-Salem, North Carolina, Verenigde Staten, 27103
- Warner Chilcott Investigational Study Site
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45249
- Warner Chilcott Investigational Study Site
-
Cleveland, Ohio, Verenigde Staten, 44122
- Warner Chilcott Investigational Study Site
-
Columbus, Ohio, Verenigde Staten, 43213
- Warner Chilcott Investigational Study Site
-
-
Pennsylvania
-
Jenkintown, Pennsylvania, Verenigde Staten, 19046
- Warner Chilcott Investigational Study Site
-
Philadelphia, Pennsylvania, Verenigde Staten, 19114
- Warner Chilcott Investigational Study Site
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15206
- Warner Chilcott Investigational Study Site
-
-
Rhode Island
-
Warwick, Rhode Island, Verenigde Staten, 02886
- Warner Chilcott Investigational Study Site
-
-
South Carolina
-
Bluffton, South Carolina, Verenigde Staten, 29910
- Warner Chilcott Investigational Study Site
-
Greer, South Carolina, Verenigde Staten, 29650
- Warner Chilcott Investigational Study Site
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78759
- Warner Chilcott Investigational Study Site
-
Dallas, Texas, Verenigde Staten, 75230
- Warner Chilcott Investigational Study Site
-
Dallas, Texas, Verenigde Staten, 75231
- Warner Chilcott Investigational Study Site
-
Dallas, Texas, Verenigde Staten, 75234
- Warner Chilcott Investigational Study Site
-
Houston, Texas, Verenigde Staten, 77030
- Warner Chilcott Investigational Study Site
-
San Antonio, Texas, Verenigde Staten, 78229
- Warner Chilcott Investigational Study Site
-
-
Utah
-
South Jordan, Utah, Verenigde Staten, 84095
- Warner Chilcott Investigational Study Site
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23507-1627
- Warner Chilcott Investigational Study Site
-
Richmond, Virginia, Verenigde Staten, 23233
- Warner Chilcott Investigational Study Site
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Warner Chilcott Investigational Study Site
-
Spokane, Washington, Verenigde Staten, 99207
- Warner Chilcott Investigational Study Site
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
35 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Vrouw
Beschrijving
Inclusion Criteria:
- Sexually active with self-identified dyspareunia (pain with sexual activity), at least moderate to severe and most bothersome symptom of vulvovaginal atrophy (VVA)
- Postmenopausal and meets 1 of the following: 12 months spontaneous amenorrhea, 6 months spontaneous amenorrhea with FSH (follicle stimulating hormone) >40 mIU/mL,6 weeks postsurgical bilateral oophorectomy with confirmation by FSH >40 mIU/mL, surgical report or ultrasound, 6 weeks postsurgical hysterectomy with ovary failure confirmed by FSH >40 mIU/mL
- Age ≥40 years; ≥35 with bilateral oophorectomy
- Vaginal pH >5.0
- Less than or equal to 5% superficial cells on vaginal wall cytologic smear
- Normal clinical breast exam or negative mammogram if ≥ 40 years of age
- Negative urine pregnancy test (non-hysterectomized and <12 months amenorrhea)
Exclusion Criteria:
- Enrollment in Sponsor's Study PR-04409 or PR-05812
- Participation in clinical trial or use of investigational drug within 30 days prior to screening
- Known hypersensitivity to estrogen and/or progestin therapy
- Known or suspected premalignant or malignant disease or history steroid-dependent malignancy
- Manifestation or treatment for significant cardiovascular disease (congestive heart failure, stroke or ischemic attack, myocardial infarction, coronary artery bypass, percutaneous angioplasty or >50% angiographic narrowing of coronary artery
- Thrombophlebitis or thromboembolic disorder or history of
- Insulin-dependent diabetes mellitus
- Increased frequency or severity of headaches while on hormone or estrogen therapy
- Currently taking St. John's Wort
- Drug/alcohol addiction within past 2 years
- Treatment with anticoagulants (heparin or warfarin)
- Smoking ≥15 cigarettes/day
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Vehicle (3 Times/Week)
Vehicle applied to the vagina daily for 14 days followed by dosing 3 times per week for 10 weeks.
|
Daily for 14 days followed by 3 times per week for 10 weeks
|
Experimenteel: WC3011 Estradiol Vaginal Cream (3 Times/Week)
WC3011 Estradiol vaginal cream applied daily for 14 days followed by dosing 3 times per week for 10 weeks.
|
Daily for 14 days followed by 3 times per week for 10 weeks
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Verandering van basislijn in het percentage vaginale oppervlakkige cellen naar definitieve beoordeling
Tijdsspanne: Basislijn (dag 0) tot definitieve beoordeling (tot week 12)
|
Van elke deelnemer werden vaginale wanduitstrijkjes verzameld.
De uitstrijkjes werden voor analyse naar het centrale laboratorium gestuurd om het percentage oppervlakkige cellen te bepalen.
Een positieve verandering ten opzichte van de basislijn wijst op verbetering.
Eindbeoordeling wordt gedefinieerd als de laatst beschikbare postbaseline beoordeling.
|
Basislijn (dag 0) tot definitieve beoordeling (tot week 12)
|
Verandering van basislijn in het percentage vaginale parabasale cellen naar eindbeoordeling
Tijdsspanne: Basislijn (dag 0) tot definitieve beoordeling (tot week 12)
|
Van elke deelnemer werden vaginale wanduitstrijkjes verzameld.
De uitstrijkjes werden voor analyse naar het centrale laboratorium gestuurd om het percentage parabasale cellen te bepalen.
Een negatieve verandering ten opzichte van de basislijn wijst op verbetering.
Eindbeoordeling wordt gedefinieerd als de laatst beschikbare postbaseline beoordeling.
|
Basislijn (dag 0) tot definitieve beoordeling (tot week 12)
|
Change From Baseline in Participant's Self-Assessment of Symptom of Vulvovaginal Atrophy (VVA): Dyspareunia (Pain Associated With Sexual Activity) to Final Assessment
Tijdsspanne: Baseline (Day 0) to final assessment (Up to Week 12)
|
Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe.
Higher score indicates the most bothersome symptoms.
A negative change from Baseline indicates improvement.
Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
|
Baseline (Day 0) to final assessment (Up to Week 12)
|
Change From Baseline in Vaginal pH to Final Assessment
Tijdsspanne: Baseline (Day 0) to final assessment (Up to Week 12)
|
Vaginal pH was obtained at baseline and final visit of the study.
The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14).
A negative change from Baseline indicates improvement.
Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
|
Baseline (Day 0) to final assessment (Up to Week 12)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change From Baseline in Participant's Self-Assessment of the Symptom of VVA: Dyspareunia to Weeks 2, 4, 8, and 12
Tijdsspanne: Baseline to Weeks 2, 4, 8 and 12
|
Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe.
Higher score indicates the most bothersome symptoms.
A negative change from Baseline indicates improvement.
|
Baseline to Weeks 2, 4, 8 and 12
|
Change From Baseline in Participant's Self-Assessment of the Other Symptoms of VVA to Weeks 2, 4, 8, 12, and Final Assessment
Tijdsspanne: Baseline (Day 0) to Weeks 2, 4, 8, 12, and final assessment (Up to Week 12)
|
Self-Assessment of the symptoms of VVA, other than dyspareunia and vaginal bleeding associated with sexual activity, (vaginal and/or vulvar irritation/itching, dysuria and vaginal dryness) were evaluated by a questionnaire.
Each symptom was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe.
Higher scores indicate the most bothersome symptoms.
A negative change from Baseline indicates improvement.
Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
|
Baseline (Day 0) to Weeks 2, 4, 8, 12, and final assessment (Up to Week 12)
|
Percentage of Participants With Vaginal Bleeding Associated With Sexual Activity at Each Visit
Tijdsspanne: Baseline (Day 0), Weeks 2, 4, 8, 12 and final assessment (Up to Week 12)
|
Vaginal bleeding associated with sexual activity was assessed by participants as either "present" or "absent".
Number of participants with assessment "present" are reported.
Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
|
Baseline (Day 0), Weeks 2, 4, 8, 12 and final assessment (Up to Week 12)
|
Change From Baseline in the Investigator's Assessment of Each of the Signs of VVA to Week 12 and Final Assessment
Tijdsspanne: Baseline (Day 0) to Week 12 and Final assessment (Up to Week 12)
|
Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to the signs of VVA: atrophy, pallor, vaginal dryness, friability, and petechiae each graded on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe.
Higher scores are worse.
A negative change from Baseline indicates improvement.
Final assessment is defined as the last available postbaseline assessment.
|
Baseline (Day 0) to Week 12 and Final assessment (Up to Week 12)
|
Change From Baseline in Vaginal pH to Week 12
Tijdsspanne: Baseline to Week 12
|
Vaginal pH was obtained at baseline and final visit of the study.
The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14).
A negative change from Baseline indicates improvement.
|
Baseline to Week 12
|
Change From Baseline in the Percentage of Vaginal Superficial Cells to Week 12
Tijdsspanne: Baseline to Week 12
|
Vaginal wall smears were collected from each participant.
The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells.
A positive change from Baseline indicates improvement.
|
Baseline to Week 12
|
Change From Baseline in the Percentage of Vaginal Parabasal Cells to Week 12
Tijdsspanne: Baseline to Week 12
|
Vaginal wall smears were collected from each participant.
The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells.
A negative change from Baseline indicates improvement.
|
Baseline to Week 12
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Studie directeur: Anna Chan, PharmD, Warner Chilcott
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
12 april 2013
Primaire voltooiing (Werkelijk)
20 november 2013
Studie voltooiing (Werkelijk)
20 november 2013
Studieregistratiedata
Eerst ingediend
25 april 2013
Eerst ingediend dat voldeed aan de QC-criteria
29 april 2013
Eerst geplaatst (Schatting)
3 mei 2013
Updates van studierecords
Laatste update geplaatst (Werkelijk)
9 mei 2022
Laatste update ingediend die voldeed aan QC-criteria
11 april 2022
Laatst geverifieerd
1 september 2021
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PR-08112
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Vulvovaginale atrofie
-
Johannes Gutenberg University MainzDentsply Sirona ImplantsOnbekendHellende atrofie van de distale onderkaak | Socket Like Atrophy van de esthetische zoneDuitsland
-
Brigham and Women's HospitalBiohaven Pharmaceuticals, Inc.VoltooidMeervoudige systeematrofie | Multiple systeematrofie, Parkinson-variant (aandoening) | Meervoudige systeematrofie, cerebellaire variant | Multiple System Atrophy (MSA) met orthostatische hypotensieVerenigde Staten
-
Theravance BiopharmaVoltooidZiekte van Parkinson | Orthostatische hypotensie | Neurogene orthostatische hypotensie | Hypotensie, orthostatisch | Puur autonoom falen | Multiple System Atrophy (MSA) met orthostatische hypotensie | Puur autonoom falen met orthostatische hypotensie | Ziekte van Parkinson met orthostatische hypotensieVerenigde Staten